NuVasive price target raised to $58 from $56 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on NuVasive to $58 from $56 and keeps an Overweight rating on the shares. The company delivered solid Q2 sales results and upside to earnings, but sales fell just shy of consensus, the analyst tells investors in a research note. While investors may question whether the business is losing momentum, NuVasive’s operating performance was solid, says the firm.